Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,356 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resolution Clear all
Completed Phase 2 Interventional Results available

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

NCT03265288
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LAU-7b, Placebo oral capsule
Drug
Lead sponsor
Laurent Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
27
States / cities
Long Beach, California • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 27, 2026, 10:41 PM EDT
Completed Phase 2Phase 3 Interventional

ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04899518
View directory record Official record
Conditions
Dry Eye
Interventions
ALY688 Ophthalmic Solution
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 27, 2026, 10:41 PM EDT
Completed Phase 3 Interventional

A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD

NCT00308191
View directory record Official record
Conditions
COPD
Interventions
Formoterol Fumarate, Tiotropium Bromide
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Sepulveda, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2008 · Synced Oct 27, 2026, 10:41 PM EDT
Completed Not applicable Interventional Results available

Effect of an Investigational Multi-Purpose Solution on Lens Moisture

NCT01341990
View directory record Official record
Conditions
Contact Lens Moisture
Interventions
FID 114675A Multi-Purpose Disinfecting Solution (MPDS), ReNu Fresh Lens Comfort Multi-Purpose Solution (MPS), Silicone Hydrogel Contact Lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2012 · Synced Oct 27, 2026, 10:41 PM EDT
Completed No phase listed Observational

Detection of Atelectasis or Pneumothorax and Resolution With Electrical Impedance Tomography (EIT) in Newborn Infants

NCT04848727
View directory record Official record
Conditions
Atelectasis Neonatal, Pneumothorax and Air Leak
Interventions
Detecting asymmetric lung disease like atelectasis or pneumothorax with electrical impedance tomography (EIT)
Other
Lead sponsor
Sharp HealthCare
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 27, 2026, 10:41 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

NCT00157079
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP), Kawasaki Syndrome
Interventions
Immune Globulin Intravenous (Human), 10%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
24 Months and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
11
States / cities
Los Angeles, California • Stanford, California • Englewood, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 27, 2026, 10:41 PM EDT
Completed No phase listed Observational Results available

The COSMOS Trial. A Pilot Study A Pilot Study

NCT05280574
View directory record Official record
Conditions
Surgery
Interventions
Blinded GE Portrait Monitoring, Unblinded GE Portrait Monitoring
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 27, 2026, 10:41 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Snapshot Adaptive Optics and Hyperspectral Autofluorescence Fundus Camera for Age-Related Macular Degeneration (AMD)

NCT03963817
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
adaptive optics AO-OCT/AF instrument
Diagnostic Test
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
60 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 27, 2026, 10:41 PM EDT
Terminated Not applicable Interventional

A Trial of Thickened Feeds to Treat Gastroesophageal Reflux in Children Admitted After Choking Spell

NCT03130543
View directory record Official record
Conditions
Apparent Life Threatening Event, Gastroesophageal Reflux, Aspiration
Interventions
Rice cereal, Enfamil AR
Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Years to 1 Year
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 27, 2026, 10:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Tear Film-Based Proteins Associated With Care Solution Induced Corneal Staining

NCT01100424
View directory record Official record
Conditions
Corneal Staining
Interventions
Opti-Free RepleniSH, ReNu MultiPlus, Balafilcon A, Unisol 4
Device · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 27, 2026, 10:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acquisition and Clinical Image Evaluation of Fujifilm's High Resolution (HR) Digital Breast Tomosynthesis (DBT) Images.

NCT07471750
View directory record Official record
Conditions
Routine Screening Mammography
Interventions
DBT HR mode image acquisition
Device
Lead sponsor
Fujifilm Medical Systems USA, Inc.
Industry
Eligibility
40 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 27, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome

NCT02682927
View directory record Official record
Conditions
Dravet Syndrome, Seizure Disorder
Interventions
ZX008 (Fenfluramine Hydrochloride), Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 27, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT06394973
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
T4090 0.2%, T4090 0.3%, Rhopressa®
Drug
Lead sponsor
Laboratoires Thea
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
24
States / cities
Glendale, Arizona • Glendale, California • Inglewood, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 27, 2026, 10:41 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol

NCT03467113
View directory record Official record
Conditions
Dravet Syndrome, Lennox Gastaut Syndrome
Interventions
ZX008 0.2 to 0.8 mg/kg/day, Cannabidiol
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 27, 2026, 10:41 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye

NCT05109702
View directory record Official record
Conditions
Dry Eye
Interventions
0.25% Tanfanercept Ophthalmic Solution, Placebo
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Glendale, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 27, 2026, 10:41 PM EDT
Terminated Phase 4 Interventional Results available

Bowel Preparation for Colonoscopy in Children

NCT01140295
View directory record Official record
Conditions
Colonoscopy Preparation
Interventions
polyethylene glycol, senna
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 27, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans

NCT04920539
View directory record Official record
Conditions
HIV Infections, Healthy
Interventions
Active Delta-9-THC
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 27, 2026, 10:41 PM EDT
Terminated Phase 2 Interventional

A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates

NCT00579020
View directory record Official record
Conditions
Corneal Infiltrates
Interventions
Moxifloxacin/dexamethasone phosphate ophthalmic solution, Moxifloxacin ophthalmic solution 0.5%, Dexamethasone phosphate solution, 0.1%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
12 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 27, 2026, 10:41 PM EDT
Completed Phase 1 Interventional

Study of 18F-Fluoro-PEG6-IPQA

NCT01320059
View directory record Official record
Conditions
Lung Cancer
Interventions
18F-PEG6-IPQA, Positron emission tomography (PET)
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 27, 2026, 10:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism

NCT01893359
View directory record Official record
Conditions
Hyperopia, Hyperopic Astigmatism
Interventions
riboflavin ophthalmic solution, 0% dextran, UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA), UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off), Laser-assisted in situ keratomileusis
Drug · Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
San Diego, California • Waltham, Massachusetts • Teaneck, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 27, 2026, 10:41 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma

NCT02855450
View directory record Official record
Conditions
Glaucoma
Interventions
rhNGF, Vehicle
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 27, 2026, 10:41 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients

NCT01174823
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
bepotastine besilate ophthalmic solution, placebo comparator ophthalmic solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 27, 2026, 10:41 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Phase 2/3 Study of IGSC, 20% in PIDD

NCT01218438
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Immune Globulin Intravenous (Human), 10% Solution, Immune Globulin Subcutaneous (Human), 20% Solution
Biological · Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
16
States / cities
Irvine, California • Centennial, Colorado • North Palm Beach, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 27, 2026, 10:41 PM EDT
Completed Not applicable Interventional

Comparison of Different Oral Rehydration Solutions

NCT02142582
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
WHO ORS, Commercial ORS
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 27, 2026, 10:41 PM EDT